11.58am: Piping specialist sees strong start to the year
Genuit Group PLC (LON:GEN) is on the move after a positive update.
The piping and ventilation specialist – formerly known as Polypipe – said it had made a good start to the year and now expected full year profits to be at the top end of the £80mln-£88mln range expected by analysts.
Three acquisitions were completed in February this year and are performing well
Its residential business benefited from merchants forward purchasing ahead of price increases, while strong new housing starts also boosted revenues. Supply problems are an issue and its costs have increased as a results, but it has managed to pass this on by raising its own prices.
Chief executive Martin Payne said: “The group has delivered a positive performance so far this year as well as completing the acquisitions of Adey, NuHeat and Plura.
“The strength of trading conditions and that of the structural growth markets we operate in, leads the board to expect that these improved trends will continue for the remainder of the first half of this year.
“There is some remaining uncertainty about how the pandemic will evolve, but the board believes the group is in a strong position to make continued progress in the current year.”
Genuit’s shares are 4.02% or 23p higher at 595p.
11.04am: Cannabis company flying
It said Pure Origin Group will manufacture, package and supply Kanabo’s cannabidiol (CBD) range from its manufacturing facility in Wales, which uses EU good manufacturing practices – a system to ensure finished products are effective and safe for distribution.
Pure Origin and Kanabo will establish a dedicated production line for the VapePod’s CBD Wellness formulas that will use Kanabo’s equipment, production protocols and IP.
Kanabo will supply raw materials to Pure Origin for the preparation of CBD formulations and final packaging. The current production line will have an initial capacity of 44,000 units a month with the ability to further increase production when necessary.
The company said the new agreement marked the end of the period of pilot sales and was the prelude to a full product launch internationally.
Its long-term strategy involves continued research and development activities to develop a range of unlicensed medical cannabis oils, which will be sold as unlicensed medical products.
Kanabo is up 6.38% at 20p.
10.21am: Power company faces working capital pressure
They are down 11.11% to 0.6p after the power company updated the market on its problems in Argentina.
It has a 50% interest in Energia del Sur, a power plant in the country owned by Patagonia Energy.
After the expiry in September of an agreement on tariffs for power generated by the plant’s steam turbine, the companies have been trying to negotiate a new deal with the regulator CAMMESA, so far to no avail.
Until a contract is signed, revenues have been set at spot prices.
Ruralec said: “If this pricing is not corrected it will have significant adverse implications for EdS’s revenue and cash generation, which in turn would affect the timing and amounts of any of the cash payments due from EdS to Patagonia Energy and ultimately to Rurelec. Since the expiry of the resolution in September 2020 the only cash the Company has received from EdS via PEL was US $224k on 23 October 2020.”
EdS has contingency plans to reduce costs, including shutting down the steam turbine. This means it is unclear whether EdS will be able to generate enough cash to pay anything to the company.
The Argentinian economy remains weak, and the government is struggling with COVID-19, which is helping to delay any resolution to the tariff talks.
Rurelec said the the future viability of EdS – the main source of funds for the company in the absence of asset sales – remains uncertain.
So Rurelec will continue to experience significant working capital pressure.
It is seeking other sources of funding, including loans from third parties, and is also looking at selling its other assets, particularly turbines in Chile and Italy.
8.29am: Pharma group signs key deals
The company, which is developing a delivery system for cancer treatments and vaccines called Nuvec, has signed material transfer agreements – the first stage towards a formal collaboration – with two pharma businesses.
The first is with an international company working in the gene therapy space.
The second is a pharmaceutical company developing its own proprietary vaccine for Covid-19 using a DNA plasmid.
N4 also gave a positive update on the latest studies on Nuvec, although some expected results may be delayed into the third quarter as the company assesses how best to make sure various pieces of research complement each other.
Chief executive Nigel Theobald said: “”We are delighted to have entered into two MTAs with these respected companies, each one addressing different markets.
“Whilst there can be no guarantee of either agreement resulting in a commercial collaboration, it marks a major step forward as we apply third party materials to Nuvec.
“Furthermore, it validates all the hard work that has been done in optimising Nuvec that major players in their fields are prepared to invest their time and resource to see how Nuvec may be applied to their technologies and IP.
The update has lifted its shares 17.72% or 1.4p to 9.3p.
A strong fourth quarter means it now expects revenues of around £83.7mln and profits of £11.5mln compared to analyst forecasts of £77.1mln-£78.5mln and £10.5mln-£11.1mln respectively.
Part of the growth came from four acquisitions during the period.
It made a point of saying the insolvency market remained suppressed due to “government financial support measures and temporary legislation changes.” Which of course has an effect on its revenues in that sector.
But it was appointed as administrators to a number of companies including Football Index, Brooks Brothers and Ralph & Russo.
Analyst Rachel May at house broker Shore Capital said: “With over 70% of Begbies’ revenue coming from counter-cyclical activities, and insolvency volumes well below historic levels, we see further upside to our forecasts as government support measures are scaled back which should result in an increase in insolvency volumes.”
Begbies is up 7.12% at 1129.4p.